Naperville, IL -- (ReleaseWire) -- 07/14/2014 --Reportstack, provider of premium market research reports announces the addition of Global Macular Edema Market 2014-2018 market report to its offering About Macular Edema

Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.

Analysts forecast the Global Macular Edema market will grow at a CAGR of 9.1 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Macular Edema market for the period 2013-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat macular edema associated with distinct etiologies.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Macular Edema market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Global Macular Edema Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Macular Edema market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
Americas
EMEA
APAC

Key Vendors
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.

Other Prominent Vendors
Alcon Inc.
Alimera Sciences Inc.
Allergan Inc.
Ampio Pharmaceuticals Inc.
iCo Therapeutics Inc.
Pfizer Inc.
Santen Pharmaceutical Co. Ltd.

Key Market Driver
Increase in Patient Population
For a full, detailed list, view our report.

Key Market Challenge
Increasing Use of Off-label Drugs
For a full, detailed list, view our report.

Key Market Trend
Increasing Recommendations by NICE
For a full, detailed list, view our report.

Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Companies Mentioned

Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen Pharmaceutical Co. Ltd.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/160983/global-macular-edema-market-2014-2018-.html

Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604